Advertisement

Topics

Search Results for "CT P6 Celltrion"

16:34 EDT 27th August 2016 | BioPortfolio

Matching Channels

None

Matching News

Korea stock? Celltrion stores Remicade biosimilar but minimises risks

Celltrion’s supply chain and warehousing procedures ensure the safe storage of Remicade biosimilars as demand fluctuates across markets, the drugmaker says.

Real-world biosimilar data driving physician acceptance, says Celltrion

Biosimilar acceptance among physicians has doubled to 80% since 2013, according to a survey presented at by copycat biologic distributor Celltrion Healthcare.

Celltrion: Data support switching to Remicade biosimilar

Celltrion Inc. (KOSDAQ:068270) presented data from 10 real-world switching studies showing that biosimilar infliximab (CT-P13) had "comparable efficacy and safety" to reference product Remicade inflix...

Pfizer introduces first and only biosimilar monoclonal antibody therapy

Michael JohnsenHospira, now a Pfizer company, entered into an agreement with Celltrion and Celltrion Healthcare in 2009 for several potential biosimilar products, including the recently-approved Infle...

Celltrion's biosimilar for J&J’s arthritis drug gets UF FDA okay

Korea-based Celltrion (Kosdaq: 068270) has received US regulatory approval for its biosimilar version of the arthritis drug marketed by Johnson & Johnson (NYSE: JNJ) and Merck & Co (NYSE: MRK)...

Celltrion/Pfizer Agree To Wait For Mid-September Inflectra Launch

Celltrion Inc. and Pfizer Inc., who have been waiting to launch their biosimilar Inflectra (infliximab-dyyb) pending an ongoing legal dispute...  

Celltrion/Pfizer's Biosimilar Launch: Three Possible Dates For Inflectra

Pfizer and Celltrion still face patent questions – and a pesky launch notification issue – after the ground-breaking US approval of their biosimilar version of Janssen's Remicade.

Many Firsts As Celltrion/Pfizer’s Inflectra Becomes Second US Biosimilar

Move over Zarxio, there's a new kid in town: Inflectra (infliximab-dyyb), which won the FDA's nod on April 5 as the first monoclonal antibody biosimilar licensed in the US, although it's going to be a...

Matching PubMed Articles

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement